Interestingly, p53 itself acts as a glucose sensor that suppresses glycolysis and proliferation by regulating the USP7–PRMT1 axis, suggesting this pathway as a therapeutic target for NSCLC patients regardless of p53 status [12]. This evidence concerns the gene USP7 and non-small cell lung carcinoma.